Serum matrix metalloproteinase type 9 in patients with coronary heart disease

Abstract

BACKGROUND: The study sends to quantify type 9 matrix metalloproteinase in serum in patients with coronary heart disease, since this enzyme is able to provoke an immunoinflammatory process leading to destabilization of atherosclerotic plaque, the development of unstable angina and acute coronary syndrome.

AIM: Is to conduct a comparative analysis of the quantitative content of MMR-9 in serum in patients with coronary heart disease (CHD) with a different course of angina and atherosclerosis and in relatively healthy individuals.

MATERIALS AND METHODS: Blood serum samples of 66 CHD patients were examined. All patients based on clinical examination were divided into 3 groups, depending on the severity of the disease. Quantitative MMR-9 analysis was performed using the Thermo Fisher ELISA kits (BMS2016-2). Determination of the amount of MMR-9 in serum was recorded in the ELX 800 ELISA reader plate. Data processing was carried out using Statistica 6.0 statistical analysis (StatSof, USA). The results were presented as means and mean errors.

RESULTS: The obtained results indicate a significant decrease in the concentration of MMR-9 in the serum of patients with an unstable course of the disease compared to the control group (relatively healthy people). This is probably due to the effect on the content and activity of its MMR-9 inhibitor TIMP-1. Further studies will investigate whether MMR-9 can be considered as a marker of destabilization of atherosclerotic plaque and act as an independent predictor of acute clinical complications in patients with cardiovascular pathology.

CONCLUSIONS: The study made it possible to establish a significant decrease in the concentration of MMR-9 in the serum of patients with an unstable course of atherosclerosis compared to the control group (relatively healthy people). In addition, in patients with an unstable course of atherosclerosis, a tendency to reduce the concentration of this enzyme compared to persons with stable atherosclerosis was revealed.

Keywords

matrix metalloproteinases / acute coronary syndrome / the pathogenesis of atherosclerosis

References

[1] Kakturskij LV. Clinical morphology of acute coronary syndrome. Arkh Patol. 2007;69(4):16–19. (In Russ.)

[2] Кактурский Л.В. Клиническая морфология острого коронарного синдрома // Архив патологии. 2007. Т. 69, № 4. С. 16–19.

[3] Pigarevsky PV, Maltseva SV, Snegova VA. Progressive atherosclerotic lesions in humans. Morphological and immune inflammatory aspects. Cytokines and inflammation. 2013;12(1–2):5–12. (In Russ.)

[4] Пигаревский П.В., Мальцева С.В., Снегова В.А. Прогрессирующие атеросклеротические поражения у человека. Морфологические и иммуновоспалительные аспекты // Цитокины и воспаление. 2013. Т. 12, № 1–2. С. 5–12.

[5] Ragino YaI, Chernyavsky AM, Polonskaya IV, et al. Contents of proinflammatory cytokines, chemoattraktants and destructive metalloproteinases in various type of unstable atherosclerotic plaques. Journal of Atherosclerosis and Dyslipidemias. 2011;(1):21–25. (In Russ.)

[6] Рагино Ю.И., Чернявский А.М., Полонская Я.В. и др. Содержание провоспалительных цитокинов, хемоаттрактантов и деструктивных металлопротеиназ в разных типах нестабильных атеросклеротических бляшек // Атеросклероз и дислипидемии. 2011. № 1. С. 21–25.

[7] Shah PK, Wang L, Sharifi B. New insights into molecular mechanisms of plaque instability. Atherosclerosis Supplements. 2006;7(3):156–157. DOI: 10.1016/S1567-5688(06)80612-4

[8] Shah P.K., Wang L., Sharifi B. New insights into molecular mechanisms of plaque instability // Atherosclerosis Supplements. 2006. Vol. 7, No. 3. P. 156–157. DOI: 10.1016/S1567-5688(06)80612-4

[9] Nanni S, Melandri G, Hanemaaijer R, et al. Matrixmetalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res. 2007;149(3):137–144. DOI: 10.1016/j.trsl.2006.09.001

[10] Nanni S., Melandri G., Hanemaaijer R. et al. Matrixmetalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms // Transl. Res. 2007. Vol. 149, No. 3. P. 137–144. DOI: 10.1016/j.trsl.2006.09.001

[11] Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41(4 Suppl S):S15–S22. DOI: 10.1016/s0735-1097(02)02834-6

[12] Shah P.K. Mechanisms of plaque vulnerability and rupture // J. Am. Coll. Cardiol. 2003. Vol. 41, No. 4 Suppl S. P. S15–S22. DOI: 10.1016/s0735-1097(02)02834-6

[13] Severgina LO. Morphogenesis of unstable atherosclerotic plaques and its role in the development of acute coronary syndrome. Arkh Patol. 2005;67(3):51–54. (In Russ.)

[14] Севергина Л.О. Морфогенез нестабильной атеросклеротической бляшки и ее роль в развитии острого коронарного синдрома // Архив патологии. 2005. Т. 67, № 3. С. 51–54.

[15] Pigarevsky PV, Maltseva SV, Tatarinov AE, et al. Matrix metalloproteinase type 1 in the blood of patients with coronary heart disease and atherosclerotic lesions in humans. Cytokines and inflammation. 2016;15(1):61–65. (In Russ.)

[16] Пигаревский П.В., Мальцева С.В., Татаринов А.Е. и др. Матриксная металлопротеиназа 1-го типа в крови больных ишемической болезнью сердца и в атеросклеротических поражениях у человека // Цитокины и воспаление. 2016. Т. 15, № 1. С. 61–65.

[17] Katunina AI, Gerstein ES, Ermilova VD, et al. Content matrix metalloproteinase 2; 7 and 9 in tumors and blood serum of breast cancer patients. Bull Exp Biol Med. 2011;151(3):359–62. DOI: 10.1007/s10517-011-1330-z

[18] Катунина А.И., Герштейн Е.С., Ермилова В.Д. и др. Содержание матриксных металлопротеиназ 2; 7 и 9 в опухолях и сыворотке крови больных раком молочной железы // Российский биотерапевтический журнал. 2010. Т. 9, № 4. С. 89–92.

[19] Markelov EV, Turmova EP, Silaev AA, et al. The value of the transforming growth factor-β and matrix metalloproteinase-9 in the pathogenesis of atherosclerosis. Russian Journal of Immunology. 2010;4(13)(3):261–266. (In Russ.)

[20] Маркелова Е.В., Турмова Е.П., Силаев А.А. и др. Значение трансформирующего фактора роста-β и матриксной металлопротеиназы-9 в патогенезе атеросклероза // Российский иммунологический журнал. 2010. Т. 4(13), № 3. С. 261–266.

[21] Vladimirskya TE, Shved IA, Yudina ОА. Expression of extracellular matrix in biomarker of atherosclerotic coronary artery lesions. Journal of Public Health. Belarus. 2016;(7):4–9. (In Russ.)

[22] Владимирская Т.Э., Швед И.А., Юдина О.А. Экспрессия биомаркеров внеклеточного матрикса при атеросклеротических повреждениях коронарных артерий // Здравоохранение. Беларусь. 2016. № 7. С. 4–9.

[23] Provatorov SI. Systemic manifestations of inflammatory reaction in coronary stentirovanii: prognostic significance and possibilities for pharmacological effects [dissertation]. Moscow; 2014. (In Russ.)

[24] Проваторов С.И. Системные проявления воспалительной реакции при коронарном стентировании: прогностическая значимость и возможности для фармакологического воздействия: дис. … канд. мед. наук. Москва, 2014.

[25] Govorin AV, Racina EV, Sokolova NA, Fetisova NV. The values of matrix metalloprotease-9 and tissue metalloprotease inhibitor-1 in acute myocardial infarction with aneurysm formation. Russian Journal of Cardiology. 2014;19(7):87–90. (In Russ.) DOI: 10.15829/1560-4071-2014-7-87-90

[26] Говорин A.B., Рацина Е.В., Соколова Н.А., Фетисова Н.В. Показатели матриксной металлопротеиназы-9 и тканевого ингибитора металлопротеиназ-1 при остром трансмуральном инфаркте миокарда, осложненном аневризмой // Российский кардиологический журнал. 2014. Т. 19, № 7. С. 87–90. DOI: 10.15829/1560-4071-2014-7-87-90

[27] Gening SO, Abakumova TV. A study of matrix of serum metalloproteinase with the progression of ovarian cancer. Advances in current natural sciences. 2013;(9):26–27. (In Russ.)

[28] Генинг С.О., Абакумова Т.В. Исследование матриксных металлопротеиназ в сыворотке крови при прогрессировании рака яичников // Успехи современного естествознания. 2013. № 9. С. 26–27.

RIGHTS & PERMISSIONS

Pigarevsky P.V., Maltseva S.V., Tanyansky D.A., Firova E.M., Tatarinov A.E., Chivikova N.V.